Wed, Aug 5, 2015
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

A concentrated portfolio pays dividends for Maglan Capital

Tuesday, October 29, 2013

amb
Steven Azarbad
Beverly Chandler, Opalesque London:

Event driven investment fund Maglan Capital saw funds increase in value by 2.51% (net of all fees) during the month of September. Over 2013, Maglan Capital has gained 34.28%, and over the most recent 12 months, Maglan Capital has gained 59.33%.

This performance is against a backdrop of September’s S&P 500 Total-Return Index being up 3.14% and the Dow Jones Credit Suisse Event-Driven Index gaining 1.45%, while over 2013, the S&P 500 Total-Return Index is up 19.79% and the Dow Jones Credit Suisse Event-Driven Index has gained 10.17%.

In a recent investor’s letter, Steven Azarbad and David D. Tawil of Maglan Capital explained their strategy, saying that a lot of things makes their firm different. "Although individual elements of our focus, strategy, portfolio and risk management and investing edges can be found in various industry participants, we think that Maglan is the only place where each of these elements (and a few elements that can’t be found anywhere) comes together" they wrote.

"We make no secret about the fact that we firmly believe that in order to outperform the general market (especially today’s equity markets; we aim for 15-20% net of fees on average over each corporate high-yield issuance and default cycle), investments must be made in a concentrated manner (we’re not shy to put on 20% positions). And, in order to have the conviction necessary to inves......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Activist News - Celgene says patent-fighting hedge fund manager wants to short its shares[more]

    From Reuters.com: Celgene Corp, one of the world's largest biotechnology companies, has accused U.S. hedge fund manager Kyle Bass of attempting to profit from his attempts to wipe out several major drug patents through his Coalition for Affordable Drugs. The company asked the U.S. Patent and T

  2. Einhorn's Greenlight Capital hedge fund slumps 6.1 percent in July[more]

    From Reuters/Thefiscaltimes.com: Hedge fund mogul David Einhorn's Greenlight Capital slumped 6.1 percent in July and is now down 9 percent for the year after gold, one of the fund's top holdings, tumbled to five-year lows last week. Greenlight notified clients of its returns late on Friday, ac

  3. Performance - Some hedge fund small-cap energy stocks have been free falling, Dan Loeb's simple strategy destroys the market, Baupost lost 1.4% last quarter as energy bargains proved elusive[more]

    Some hedge fund small-cap energy stocks have been free falling From Marketrealist.com: According to a July 28, 2015, Bloomberg article, there was a 34% fall in small-cap energy stocks over the past three months. These shares are tracked by the Russell 2000 Energy Index. Small-cap energy

  4. Legal - Hedge funds hit Rothstein Kass with $75m malpractice suit, JPMorgan questioned on private bank’s hedge fund disclosures, Kijani fund, seized by regulators in Cayman Islands, spotlights risks in lightly regulated market[more]

    Hedge funds hit Rothstein Kass with $75m malpractice suit From Law360.com: Two investment funds have sued Rothstein Kass & Co. PC for at least $75 million, claiming the New Jersey auditing firm committed accounting malpractice by failing to properly scrutinize overblown valuations of the

  5. Assets - Hedge funds are getting smoked by the commodities slump, Global ETF assets could more than double by 2020[more]

    Hedge funds are getting smoked by the commodities slump From Businessinsider.in: The collapse in commodity prices has burnt another hedge fund. Vermillion, a commodity hedge fund backed by Carlyle Group, has seen its flagship fund's assets fall from nearly $2 billion to less $50 million,

 

banner